NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.41 -0.16 (-2.44 %) (As of 09/21/2018 04:00 PM ET)Previous Close$6.41Today's Range$6.29 - $6.6152-Week Range$5.01 - $9.42Volume4.39 million shsAverage Volume1.56 million shsMarket Capitalization$495.11 millionP/E Ratio-7.12Dividend YieldN/ABeta2.39 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York. Receive PGNX News and Ratings via Email Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:PGNX CUSIP74318710 Webwww.progenics.com Phone646-975-2500 Debt Debt-to-Equity Ratio0.68 Current Ratio6.34 Quick Ratio6.34 Price-To-Earnings Trailing P/E Ratio-7.12 Forward P/E Ratio-9.57 P/E GrowthN/A Sales & Book Value Annual Sales$11.70 million Price / Sales41.29 Cash FlowN/A Price / CashN/A Book Value$0.90 per share Price / Book7.12 Profitability EPS (Most Recent Fiscal Year)($0.90) Net Income$-51,010,000.00 Net Margins-341.41% Return on Equity-94.45% Return on Assets-40.08% Miscellaneous Employees64 Outstanding Shares75,360,000Market Cap$495.11 million Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions What is Progenics Pharmaceuticals' stock symbol? Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX." How were Progenics Pharmaceuticals' earnings last quarter? Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Tuesday, July, 31st. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.02. The biotechnology company earned $3.88 million during the quarter, compared to analysts' expectations of $3.30 million. Progenics Pharmaceuticals had a negative net margin of 341.41% and a negative return on equity of 94.45%. View Progenics Pharmaceuticals' Earnings History. When is Progenics Pharmaceuticals' next earnings date? Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Progenics Pharmaceuticals. What price target have analysts set for PGNX? 3 brokers have issued 1 year price targets for Progenics Pharmaceuticals' stock. Their forecasts range from $12.00 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $13.3333 in the next twelve months. This suggests a possible upside of 108.0% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals. What is the consensus analysts' recommendation for Progenics Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals. What are Wall Street analysts saying about Progenics Pharmaceuticals stock? Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock: 1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (9/11/2018) 2. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating and 12-month PT of $15 on the shares of PGNX. Although we like the rare disease opportunity for AZEDRA (PDUFA 7/30), we also like the PSMA-targeted pipeline for prostate cancer. Moreover, what we have come to appreciate in the PGNX story is the optionality of the pipeline, which extends to the potential for out-licensing, financing and clinical development." (5/20/2018) Are investors shorting Progenics Pharmaceuticals? Progenics Pharmaceuticals saw a drop in short interest in the month of August. As of August 15th, there was short interest totalling 10,685,973 shares, a drop of 12.0% from the July 31st total of 12,139,680 shares. Based on an average daily volume of 2,922,747 shares, the short-interest ratio is presently 3.7 days. Currently, 14.5% of the shares of the stock are sold short. View Progenics Pharmaceuticals' Current Options Chain. Who are some of Progenics Pharmaceuticals' key competitors? Some companies that are related to Progenics Pharmaceuticals include Prestige Consumer Healthcare (PBH), G1 Therapeutics (GTHX), Mirati Therapeutics (MRTX), Allakos (ALLK), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Puma Biotechnology (PBYI), Myovant Sciences (MYOV), Zogenix (ZGNX), Phibro Animal Health (PAHC), Clovis Oncology (CLVS), Corcept Therapeutics (CORT), Nabriva Therapeutics (NBRV), Insmed (INSM) and Arrowhead Pharmaceuticals (ARWR). Who are Progenics Pharmaceuticals' key executives? Progenics Pharmaceuticals' management team includes the folowing people: Mr. Mark R. Baker, CEO & Director (Age 63)Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 50)Dr. Vivien Wong, Exec. VP of Devel. (Age 61)Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 45)Mr. Benedict Osorio, Sr. VP of Quality (Age 61) Has Progenics Pharmaceuticals been receiving favorable news coverage? News headlines about PGNX stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Progenics Pharmaceuticals. Who are Progenics Pharmaceuticals' major shareholders? Progenics Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.12%), Federated Investors Inc. PA (9.28%), Eagle Asset Management Inc. (5.92%), Pinnacle Associates Ltd. (2.37%), Phocas Financial Corp. (2.34%) and Rice Hall James & Associates LLC (1.89%). View Institutional Ownership Trends for Progenics Pharmaceuticals. Which institutional investors are selling Progenics Pharmaceuticals stock? PGNX stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Baker BROS. Advisors LP, Pinnacle Associates Ltd., Fisher Asset Management LLC, Bank of America Corp DE, California Public Employees Retirement System, Phocas Financial Corp. and Alps Advisors Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals. Which institutional investors are buying Progenics Pharmaceuticals stock? PGNX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Northern Trust Corp, Creative Planning, Trexquant Investment LP, Schwab Charles Investment Management Inc., Employees Retirement System of Texas and Bank of New York Mellon Corp. View Insider Buying and Selling for Progenics Pharmaceuticals. How do I buy shares of Progenics Pharmaceuticals? Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Progenics Pharmaceuticals' stock price today? One share of PGNX stock can currently be purchased for approximately $6.41. How big of a company is Progenics Pharmaceuticals? Progenics Pharmaceuticals has a market capitalization of $495.11 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe. How can I contact Progenics Pharmaceuticals? Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected] MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 530MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: What is the NASDAQ?